Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK or trading as Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Nozinan 25mg/ml Solution for Injection/Infusion.
| Pharmaceutical Form |
|---|
|
Solution for injection/infusion. Clear, colourless solution contained in a clear glass ampoule. |
Levomepromazine hydrochloride 25mg per ml.
For excipients, see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levomepromazine |
Levomepromazine resembles chlorpromazine and promethazine in the pattern of its pharmacology. It possesses anti-emetic, antihistamine and anti-adrenaline activity and exhibits a strong sedative effect. |
| List of Excipients |
|---|
|
Ascorbic acid |
Colourless type I glass ampoule. Each pack contains 10 ampoules.
Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
or trading as
Sanofi-aventis or Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
PL 04425/0659
12th June 2009
| Drug | Countries | |
|---|---|---|
| NOZINAN | Austria, Canada, Estonia, France, Croatia, Ireland, Malta, Netherlands, New Zealand, Tunisia, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
